01541.HK
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 3.40
+0.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 274.4M | 150.3M | 74.1M | 386.0K | 5.7M |
| Cost of Revenue | 8.2M | 15.3M | — | (38.7K) | — |
| Gross Profit | 266.2M | 135.0M | 74.1M | 7.7M | 5.7M |
| Operating Expenses | |||||
| R&D Expense | 670.2M | 313.9M | 322.8M | 291.9M | 277.3M |
| SG&A Expense | 96.3M | 38.3M | 64.8M | 80.4M | 92.8M |
| General & Admin Expense | 85.2M | — | 64.8M | 80.4M | 92.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.1M | — | (5.4M) | — | — |
| Total Operating Expenses | 768.6M | 352.3M | 382.2M | 372.4M | 370.1M |
| Cost and Expenses | 789.6M | 367.6M | 382.2M | 365.1M | 370.1M |
| Operating Income (EBIT) | (515.1M) | (217.3M) | (308.0M) | (364.7M) | (364.5M) |
| Non-Operating | |||||
| Interest Income | 9.6M | 6.7M | 6.4M | 10.8M | 9.5M |
| Interest Expense | 7.0M | 5.2M | 3.4M | 1.5M | 787.0K |
| Net Interest Income | 2.6M | 1.5M | 2.9M | 9.3M | 8.7M |
| Other Non-Op Income/Expense | (19.3M) | 3.7M | (8.5M) | (14.8M) | (38.4M) |
| Non-Operating Income (excl Interest) | — | — | — | 13.3M | 19.9M |
| EBT (Pre-Tax Income) | (534.5M) | (213.6M) | (316.6M) | (379.5M) | (402.9M) |
| Income Tax Expense | 51.5K | 28.2K | — | — | — |
| Bottom Line | |||||
| Net Income | (529.5M) | (212.9M) | (315.9M) | (379.5M) | (402.9M) |
| Earnings from Cont. Ops | (534.5M) | (213.6M) | (316.6M) | (379.5M) | (402.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (529.5M) | (212.9M) | (315.9M) | (379.5M) | (402.9M) |
| Per Share | |||||
| Basic EPS | (HK$1.31) | (HK$0.51) | (HK$0.84) | (HK$1.05) | (HK$1.08) |
| Diluted EPS | (HK$1.31) | (HK$0.51) | (HK$0.84) | (HK$1.05) | (HK$1.08) |
| Revenue Per Share | HK$0.64 | HK$0.36 | HK$0.20 | HK$0.00 | HK$0.02 |
| Shares | |||||
| Basic Shares Outstanding | 431.4M | 412.4M | 377.2M | 361.8M | 373.2M |
| Diluted Shares Outstanding | 431.4M | 412.4M | 377.2M | 361.8M | 373.2M |
| Profitability Metrics | |||||
| EBITDA | (501.8M) | (203.0M) | (295.6M) | (355.4M) | (384.5M) |
| D&A | 24.2M | 14.2M | 12.4M | 22.6M | 17.6M |
| EBIT | (528.2M) | (217.3M) | (308.0M) | (377.9M) | (402.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026